Acadia Pharmaceuticals Inc (ACAD) stock
Close on Nov 11, 2026Market cap $3.17BP/E 8.7Yield –
Acadia Pharmaceuticals Inc grew revenue 14.8% to $1.20B over the twelve months to Sep 30, 2026. Operating income fell 49.2% to $122.33M, moving the operating margin from 23.0% to 10.2%. Free cash flow was $81.99M, down 58.6% from a year earlier. At the latest close the market valued the company at $3.17B, 8.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.17B
- P/E ratio
- 8.7
- Price to sales
- 2.63
- Price to book
- 2.28
- Dividend yield
- –
- Free cash flow yield
- 2.59%
Fundamentals
- Revenue
- $1.20B
- Net income
- $362.23M
- EPS, diluted
- $2.10
- Free cash flow
- $81.99M
- Book value per share
- $7.91
- Diluted shares
- 175M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $18.28
- Open
- $18.13
- Day's range
- $17.90 – $18.58
- Volume
- 2,395,219
- Average volume (20 days)
- 2,693,042
- Index membership
- S&P SmallCap 600 (since Feb 2025), Russell 2000 (since Jun 2021), Russell 3000
- Beta (5 years)
- 0.78
- 52-week range
- $15.86 – $30.96
- RSI (14 days)
- 38.9
- Volatility (1 year)
- 45.7%
- Relative volume
- 1.19×
- WACC
- 8.8%
On 2 of our idea lists: Undervalued and financially sound, Fallen quality
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACAD | S&P 500 | Difference | ACAD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.1% | -2.4% | −4.7 pts | ||
| 3 months | -37.5% | -1.2% | −36.4 pts | ||
| Year to date | -31.2% | +12.3% | −43.5 pts | ||
| 1 year | -22.6% | +12.4% | −35.0 pts | ||
| 3 years | -17.3% | +78.8% | −96.1 pts | -6.1% | +21.4% |
| 5 years | -11.2% | +75.2% | −86.3 pts | -2.3% | +11.9% |
| 10 years | -36.2% | +311.1% | −347.3 pts | -4.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Acadia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Results
- Results
About Acadia Pharmaceuticals
Pharmaceutical Preparations
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological and rare diseases. The company operates two main commercial franchises focused on addressing underserved medical conditions. Its primary commercial products include Nuplazid, a treatment for hallucinations and delusions linked to Parkinson’s disease psychosis, and Daybue, approved for the treatment of Rett syndrome. Acadia distributes its pharmaceutical products through a specialized network of third-party specialty pharmacies and distributors to reach patients, healthcare providers, and caregivers.
Company profile, executives and historyAcadia Pharmaceuticals stock: common questions
What is Acadia Pharmaceuticals's stock price?
ACAD closed at $18.37 on Nov 11, 2026, up 0.49% on the day. Over the past 52 weeks it traded between $15.86 and $30.96.
What is Acadia Pharmaceuticals's market cap?
Acadia Pharmaceuticals was worth $3.17B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACAD's P/E ratio?
ACAD trades at 8.7 times earnings, based on diluted earnings per share of $2.10 over the twelve months to Sep 30, 2026.
How much revenue does Acadia Pharmaceuticals make?
Acadia Pharmaceuticals reported revenue of $1.20B for the twelve months to Sep 30, 2026, up 14.8% from a year earlier.
Does Acadia Pharmaceuticals pay a dividend?
No. Acadia Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Acadia Pharmaceuticals report earnings next?
Acadia Pharmaceuticals is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ACAD stock performed over the past year?
Including dividends, ACAD returned -22.6% over the past year, against +12.4% for the S&P 500.
How many ACAD shares are sold short?
8M shares were sold short at the latest FINRA report, 6.68% of the float, or 5.9 days of average trading volume.
Who are Acadia Pharmaceuticals's competitors?
Companies most similar to Acadia Pharmaceuticals by business, industry and size include PTCT, HRMY, ALKS, INSM, BBIO.
See a number that looks wrong?